Although ERBB2 amplification and overexpression is correlated with poor outcome in breast cancer, the molecular mechanisms underlying the aggressive nature of these tumors has not been fully elucidated. 
Introduction
The progression of normal mammary epithelial cells to a malignant phenotype involves multiple genetic events including amplification and overexpression of proto-oncogenes, such as ERBB2 (Neu, HER2) [1] . ERBB2 amplification and subsequent overexpression strongly correlates with a negative clinical prognosis in both lymph node-positive and -negative breast cancer [2] . Direct evidence supporting a role for ERBB2 in human breast cancer derives from observations made with transgenic mice. Overexpression of activated ErbB2 in the mammary epithelium results in the rapid induction of metastatic multifocal mammary tumors (reviewed in [3] ). One limitation of these studies is that ErbB2 expression is driven by the hormonally regulated mouse mammary tumor virus (MMTV) promoter, resulting in non-physiological expression of the transgene. In an attempt to more closely mimic the events involved in ErbB2-induced mammary tumor progression, we have generated transgenic mice that carry a Cre-inducible activated erbB2 allele under the transcriptional control of the endogenous erbB2 promoter (herein referred to as the ErbB2 KI model) [4] . In contrast to the rapid tumor progression observed in the MMTV-regulated ErbB2 strains, focal mammary tumors arose only after an extended latency period in the ErbB2 KI model, and this was further associated with a dramatic elevation of both ErbB2 protein and transcript. Remarkably, the elevated expression of ErbB2 was correlated with the selective genomic amplification of the activated erbB2 allele. Thus, as in human breast cancers, amplification of erbB2 appears to be a critical event in mammary tumor progression in this unique transgenic mouse model (reviewed in [3] ).
Another critical event in the development of human cancer is the dysregulation or mutational activation of the Wnt/β-catenin signaling axis [5] . β-catenin is a multifunctional protein that plays a vital structural role in cadherin-based cell adhesion, and is an important transcriptional activator of canonical Wnt-mediated gene expression [6, 7] . Activation of the 5 metastasis in these tumor cells, and was further associated with reduced expression of components of the erbB2 amplicon as well as ErbB3. Moreover, treatment of ErbB2 KI tumor cells with ICG-001, an inhibitor that specifically antagonizes β-catenin/CBP-mediated transcription which is critical for maintenance of a non-differentiated/proliferative state [12, 13] , resulted in a proliferative defect, which was accompanied with reduced expression of ErbB2. Similarly, treatment of human ERBB2-positive breast cancer cells with ICG-001 significantly decreased cell proliferation, which correlated with reduced levels of ErbB2.
These observations demonstrate that targeting of β-catenin-dependent signaling has potential therapeutic value in the treatment of the basal category of ERBB2-positive breast cancer.
Materials and Methods
Gene expression microarray data. Total RNA was isolated from five individual ErbB KI tumors. Given the homogeneity of the MMTV/NIC model, two RNA pools containing equal amounts of total RNA from five individual tumors were generated to obtain MMTV/NIC profiles that are representative of the general population [14] . Total RNA isolation and RNA sample preparations were performed as previously described [14] . Labelled aRNA (750ng) was hybridized against a Universal Mouse Reference RNA (Stratagene) onto Agilent Whole
Mouse Genome Oligo Microarrays (G4122A; 44K). Duplicate hybridizations were done for all samples using reverse-dye labelling. Microarray data analysis was carried out in the R statistical programming environment (R Development Core Team, 2008) with Bioconductor [15] . Raw and normalized data can be found in NCBI GEO (GSE37954). Detailed data management are provided in Supplementary Methods and Supplementary Table 1 .
qRT-PCR analysis. Total RNA was isolated from flash frozen mammary tumor tissue using 
Histology and immunostaining of tissue sections. Mammary tumors and lungs were
harvested from mice at tumor endpoint. Tissue was fixed and embedded as described previously [16] . Paraffin sections of 5 μm were stained with hematoxylin and eosin (H&E).
Step sections of lungs (5 x 50 μm) were scanned using a Scanscope XT Digital Slide Scanner (Aperio) and analyzed at 5X magnification using Imagescope software (Aperio) to quantify 7 the total number and surface area of lesions per lung. Immunostaining was performed as described [17] (SI Materials and Methods).
Immunoblotting. Tumor lysates were prepared from flash frozen tissue and immunoblot analyses were performed on 15μg of lysate as described [14] . For cell lines, extract was prepared in RIPA lysis buffer and 15μg of lysate was used for immunoblot analyses.
Antibodies for immunoblots include: c-Myc, Neu (C18), ErbB3 (C17), and Grb7 from Santa
Cruz; β-catenin, survivin, Egfr, and tubulin from Cell Signaling, and β-actin from Sigma
Aldrich. Horseradish peroxidase-conjugated secondary antibodies were obtained from Jackson Laboratories.
Cell culture, retroviral transduction, and orthotopic transplants. Human breast cancer cell lines (MCF7, SKBR3, HCC202, HCC1954, and MDAMB231 (ATCC)) were maintained according to recommendations. ErbB2 KI -derived tumor cells (TM15c7-2 and c10-2) were maintained in DMEM supplemented with 10% fetal bovine serum and SingleQuots (Clonetics). TM15 cell lines expressing shRNAmirs targeting β-catenin or non-silencing shRNA control (Open Biosystems) were generated by retroviral transduction according to the manufacturer's instructions followed by puromycin selection (4ȝg/ml, Sigma Aldrich). For orthotopic transplants, TM15c10-2 cells (1.5 × 10 5 cells in PBS solution) were injected into the no. 4 inguinal mammary fat pad of athymic nude mice (Taconic). Mice were monitored twice weekly for tumor formation and tumor growth was assessed by weekly calliper measurements. Mice were sacrificed and tissues were harvested once the tumor volume reached 2000 mm 3 . All experiments involving mice were conducted in accordance with
McGill University animal care guidelines.
Proliferation assay. CellTiter Aqueous MTS (Promega) proliferation assays were performed according to the manufacturer's protocols using 2500 (TM15c10-2, c7-2) and 5000 Hospital, Sydney, H00 036). A more detailed description of the clinicopathological characteristics of the cohort is published elsewhere [19, 20] (SI Materials and Methods). β-catenin status has previously been determined for this cohort as described [19] (SI Materials and Methods).
Definition of intrinsic "molecular" phenotype of breast cancer. This was assessed immunohistochemically using criteria similar to those previously described [21] and FISH to determine ERBB2 status [20] . Four different subgroups were defined: basal, ERBB2 + /ER -/PR -, luminal A and B. Statistical evaluation was performed using Statview 5.0 Software (Abacus Systems, Berkeley, CA). A p-value of less than 0.05 was accepted as statistically significant. Analysis of variance was used to determine differences in expression of continuous variables across breast cancer subtypes as previously described [22] . KaplanMeier analysis and Cox-proportional hazard ratios were used to determine association of membrane to cytoplasmic (MTC) score < 0 with breast cancer specific death [19] (SI Materials and Methods). (Fig. 1, upper panel) . However, many of these tumors retained expression of basal cytokeratin markers such as Krt5, Krt6, and Krt14 (Fig. 1, Fig. S1A ). A similar heterogeneous expression was observed for Trp63
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and Egfr, which are also associated with a basal phenotype (Fig. 1, Fig. S1A ). By contrast, MMTV/NIC tumors were exclusively Krt8-positive but negative for these basal markers ( Fig.   1 gl.). Using a class discovery approach with those genes that varied most across the dataset, the samples primarily cluster into two defined groups which completely separate the normal controls (FVB m. gl.) from the tumors (Fig. S3A ). The analysis further segregates the two ErbB2 mouse models into two distinct subclusters (Fig. S3A) . Notably, the ErbB2 KI tumorderived profiles displayed heterogeneous gene expression patterns. Among the genes showing increased transcriptional abundance uniquely in ErbB2 KI tumors were components and targets of the Wnt/β-catenin pathway and genes that are linked to the TGFβ signaling pathway ( Fig. 2A) . Moreover, basal cytokeratins displayed altered transcript levels, supporting our initial immunohistochemical analyses ( Fig. 1 ).
To understand the molecular differences between tumors derived from the two ErbB2 models, genes systematically upregulated in each of the models were analyzed for enrichment in GO and KEGG pathways (Supplementary Table 1 ). Although the two ErbB2-driven tumor models shared a number of common signaling pathways (Supplementary Table   1 ).
Recently, a murine-specific tumor dataset and intrinsic gene list have been established from transgenic mouse models that resemble the intrinsic subtypes of human breast cancer based on their gene expression [26] . Using this murine-specific intrinsic gene list and tumor dataset, unsupervised hierarchical clustering assigned the ErbB2 KI and MMTV/NIC models to distinct molecular groups ( Next, we explored how the transcriptional profiles generated from two different ErbB2 breast cancer mouse models correspond to the human disease. ErbB2 tumor-derived gene expression profiles were compared to profiles from human breast cancers using a crossspecies intrinsic gene set as a basis [26] . Consistent with our results obtained from the intramouse model comparison, the MMTV/NIC tumors clustered with the human luminal subtypes while the ErbB2 KI tumors clustered within the human ERBB2 subtype (Fig. 3A) . To preclude the influence of the erbB2 amplicon on human subtypes in this cross-species β-catenin targets (Fig.4B-D) . Consistent with the inherent intratumoral heterogeneity observed in ErbB2 KI mammary tumors, there was a high degree in variability in the expression of these β-catenin targets within the ErbB2 KI cohort.
Cytoplasmic and nuclear β-catenin accumulation has been commonly observed in poor outcome basal-like breast cancers that express ErbB2 [19, 31] . Additionally, recent studies have shown that ERBB2-overexpressing tumors can be subdivided in different groups based on their estrogen receptor (ER) status and the expression of basal cytokeratins [23, 32] .
To establish whether subcellular β-catenin localization impacts on either ER status or the expression of basal cytokeratins, we performed further statistical analyses of our previously described patient cohort [19] . The results demonstrated that tumors with significantly higher cytoplasmic β-catenin (reflected by the "membrane to cytoplasmic" MTC score <0 [19] ) segregated predominantly to the basal-like and ERBB2 + /ER -/PR -subtypes (Fig. 5A, B) . One striking feature of these cell lines is the difference in their ability to metastasize to lung, with two clones being highly metastatic (TM15c7-2 and c10-2) [33] . To this end, stable c7-2 and c10-2 cell lines expressing either nonspecific shRNA or shRNAs targeting β-catenin (shCtnnb1) were generated. Although the in vitro growth rates of the pooled clones expressing β-catenin shRNA were comparable to the growth rates of the controls (Fig. S4A) , the β-catenin-knockdown cells exhibited a pronounced defect in invasion in contrast to the control cells (Fig. S4B) . Immunoblot analyses confirmed reduced β-catenin protein levels in both cell lines expressing β-catenin-specific shRNAs (Fig. S4C-D) . Interestingly, in addition to the reduced levels of β-catenin, immunoblot analyses also detected a decrease in ErbB2
( Fig. S4C-D) . Similar data were obtained for a different set of β-catenin-specific shRNAs (Fig. S4D) , indicating that loss of β-catenin results in a reduction in ErbB2 protein levels.
To assess whether β-catenin-deficiency could alter the in vivo tumorigenic potential of these cells, the tumor cells were injected into the mammary fat pad of athymic mice and monitored for mammary tumor induction. While control mice exhibited rapid induction of mammary tumors, TM15c10-2 tumor cells expressing the β-catenin shRNA showed a substantial delay in tumor onset (Fig. 6A) . In addition to the effect on tumor onset, the (Fig. 6B) . Similarly, the average total surface area of these lesions was dramatically reduced in the mice injected with the β-catenin-deficient tumor cells when compared to surface area of lesions in the control groups (Fig. S5A) .
Since β-catenin-deficient ErbB2 KI cells exhibited low levels of ErbB2 protein ( Fig.   S4C-D) , we next examined the expression of ErbB2 in mammary fat pad outgrowths of ErbB2 KI cell lines lacking β-catenin and control groups. Consistent with our in vitro studies, β-catenin-deficient tumors showed a significant decrease in ErbB2 protein and transcript levels, while relative erbB2 amplification was unchanged across all samples (Fig. 6C, Fig.   S5B ). Moreover, given the strong correlation between the expression of ErbB2, ErbB3 and components of the erbB2 amplicon, including Grb7, Stard3 and Perld1, we assessed their expression in these samples [34, 35] . Like ErbB2 levels, the expression of these proteins was significantly reduced in β-catenin-deficient mammary tumors, (Fig. 6C ).
To verify that β-catenin signaling was impaired in these tumors, the relative expression of several β-catenin target genes was measured by qRT-PCR analysis. Indeed, significant decrease in β-catenin, Axin2, and Tcf7 transcripts were detected in most of the β-catenin-deficient tumors, as well as reduced expression of CyclinD1 (Fig. S5C, D) . These observations indicate that β-catenin is critical for both the initiation and metastatic phases of prevents β-catenin/CBP-mediated transcription, which is critical for maintenance of a nondifferentiated/proliferative state, without affecting β-catenin/p300-dependent signaling, which is important for initiation of cellular differentiation [12, 13] . Treatment of two independent ErbB2
KI -derived tumor cell lines (TM15c7-2, c10-2) with ICG-001 resulted in a clear proliferative defect in both cell lines without impacting the apoptotic status of the cells (Fig. 6D left panel) . In contrast, proliferation in two independent MMTV/NIC-derived tumor cell lines was not affected by ICG-001 treatment (Fig. S5E ), supporting our data that β-catenin signaling is not activated in this MMTV-driven ErbB2 mouse model.
Biochemical analyses of ICG-001-treated ErbB2
KI cells revealed lower levels of survivin, a β-catenin/CBP-regulated target gene [36] , in these cells (Fig. 6D, right panel) .
Like β-catenin-deficient ErbB2 KI tumor cells, specific inhibition of the β-catenin/CBP signaling resulted in reduced expression of ErbB2, Egfr, Grb7 and ErbB3 (Fig. 6D, right panel). Collectively, these observations argue that inhibition of β-catenin/CBP function severely affected ErbB2 KI tumor cell proliferation accompanied by a reduction in the levels of Egfr family members (ErbB2, ErbB3, Egfr) and Grb7.
To confirm the importance of β-catenin /CBP signaling in human ERBB2-dependent breast tumor progression, we evaluated whether ICG-001 impacts on the proliferative status of a number of ERBB2-expressing human breast cancer cell lines. Given the association of β-catenin signaling with ERBB2-overexpressing breast cancer cells that are ER/PR-negative, we evaluated the β-catenin status in three such lines (HCC202, HCC1954, SKBR3) [37] .
Immunofluorescence analysis using β-catenin and activated β-catenin antibodies revealed the presence of activated β-catenin in the nucleus in all three ERBB2 + /ER -/PR -cell lines ( (Fig. 7B, Fig. S6B ). By contrast, ICG-001 had a modest effect on cell proliferation in the luminal control cancer cell line (MCF7) (Fig. S6B) . The observed ICG-001-mediated proliferative defect was not associated with an increase in apoptosis as cell surface Annexin V staining was unaffected (Fig. S6C) .
Consistent with impaired β-catenin/CBP signaling, biochemical analyses of ICG-001-treated tumor cells in comparison with DMSO-and untreated cells exhibited significantly reduced levels of survivin in the basal and all three ERBB2-positive cell lines (Fig. 7C, Fig.   S6D ). Moreover, in support with our data obtained from ErbB2 KI tumor cells, ERBB2-overexpressing human cell lines displayed substantially lower levels of ERBB2, GRB7, ERBB3, and EGFR when treated with ICG-001 (Fig. 7C) . Together, these data suggest that targeting β-catenin/CBP signaling results in the repression of ERBB2 and an associated decrease in cell proliferation amongst ERBB2-overexpressing breast cancer cell lines.
To this end our data indicate that antagonizing β-catenin signaling leads to repression of ErbB2/ERBB2 expression in both mouse and human mammary tumor cells. To explore whether β-catenin directly activated ERBB2 transcription, we performed ChIP analyses on the ERBB2 promoter with β-catenin-and RNA polymerase II-specific antisera. Although we could not detect recruitment of β-catenin to the ERBB2 proximal promoter, we detected a 3-fold enrichment in β-catenin and a 20-fold enrichment in RNA polymerase II recruitment to an intronic ERBB2 site (Fig 7D) , which has been shown to be bound by several factors that are important in the transcriptional regulation of ERBB2 [18, 38] . β-catenin and RNA polymerase II occupancy to this site was further enriched upon treatment with the Wnt3 ligand ( Fig 7D) . We further exposed the cells to ICG-001 for 48 hours and there was no impact on recruitment of ȕ-catenin to the intronic ERBB2 site (data not shown) whereas RNA polymerase II occupancy was substantially decreased (Fig 7D) . Importantly, activation by Wnt/β-catenin signaling in SKBR3 cells led to a 2-fold increase in the recruitment of RNA polymerase II to the promoter of ERBB2, while inhibition of ȕ-catenin/CBP by ICG-001 decreased RNA polymerase II recruitment by 2-fold (Fig 7D) . Interestingly, we observed a similar impact on RNA polymerase II occupancy on the proximal promoter of other components of the ERBB2 amplicon after Wnt3 and ICG-001 treatment (Grb7, Stard3, and PerlD1; Fig S6E) . Together, these data indicate that β-catenin/CBP-mediated signaling directly regulates ERBB2 expression in ERBB2-positive breast cancer cells. , and normal-like) that are associated with differences in patient outcome and response to treatment [39] . A growing body of evidence established by transcriptional profiling, comparative genome hybridization, and immunohistochemical analyses, suggests that the biology of ERBB2-positive tumors is similarly heterogeneous. Indeed, this molecular subtype can be subdivided into ER-positive and ER-negative tumors, which may explain the variable response to ERBB2-targeted therapy [23, 32, [40] [41] [42] [43] . To address this issue, we employed the ErbB2 KI mouse model, which exhibits several unique features, including expression of ErbB2 from its endogenous promoter and spontaneous amplification of the erbB2 locus, resembling that of human ERBB2-positive breast cancers [4] . In this study, we
showed that ErbB2 KI mammary tumor progression is associated with heterogeneous expression of distinct basal (Krt5, Krt6, Trp63, and Egfr), myoepithelial (Krt14) and luminal markers (Krt8), and the presence of cells exhibiting bipotential characteristics, whereas constitutive MMTV/NIC tumors are comprised of a uniform luminal epithelial cell type ( Fig.   1 , S1, S2).
Consistent with these histopathological features, the gene expression signatures from ErbB2 KI mammary tumors differ from those of MMTV/NIC tumors ( Fig. 2A) 
ErbB2-driven expression profiles with data derived from other murine models revealed that
ErbB2
KI samples shared molecular features with murine models representative of the mesenchymal/basal phenotype (Fig. 2B) . Using an intrinsic mouse/human signature [26] , we further demonstrated that ErbB2 KI mammary tumors closely resemble both the basal-like and ERBB2-positive subtypes of human breast cancer (Fig. 3) . By contrast, MMTV/NIC tumors exhibited transcriptional features typical of the solid/luminal subtype (Fig. 3) . Since high ErbB2 expression is achieved much earlier in the MMTV/NIC strain in comparison to ErbB2 KI mice, it is likely that the tumor-initiating cell type may differ between the two models. In support of this argument, ErbB2 KI mammary tumors contain cells expressing
Trp63 and co-expressing Krt8/14 and Krt8/5 ( Fig. 1, S1 , S2), which are indicative of a multipotent phenotype [44, 45] .
Based on our gene expression data we found that ErbB2 KI mammary tumors overexpressed components of the Wnt/β-catenin signalling pathway, contained cellular regions with nuclear β-catenin, and abundantly expressed classical Wnt/β-catenin targets, including CyclinD1, c-Myc, Axin2, and Tcf7 (Fig. 2, 4 ). These findings indicate that ErbB2 KI mammary tumor progression is associated with Wnt/β-catenin activation. Consistent with this concept, recent genomic and immunohistochemical profiling of human ERBB2-amplified tumors identified an ERBB2 + /ER -subgroup that was associated with the accumulation of cytoplasmic β-catenin, overexpression of Wnt/β-catenin signaling components, and increased risk of recurrence [41] . We identified a subgroup within our ERBB2-positive patient cohort characterized as ERBB2 + /ER -/PR -, which predominantly displayed cytoplasmic β-catenin and was associated with poor clinical outcome (Fig. 5) . Collectively, these observations suggest that mammary tumor progression in the ErbB2 KI mouse model recapitulates many of the molecular events observed in the human basal-ERBB2 subtype, including activation of a β-catenin signaling network. CAN-12-3925 The importance of β-catenin signaling in ErbB2 mammary tumorigenesis is further highlighted by the observation that downregulation of endogenous β-catenin expression in
KI -derived mammary tumor cells (TM15c7-2 and c10-2) severely impaired the invasive capacity of these cells in vitro (Fig. S4) and impacted both the initiation and metastatic phases of tumor progression in vivo (Fig. 6 ). Our observations are consistent with numerous reports where genetic ablation of β-catenin in various in vivo systems diminished metastatic progression [46, 47] , providing support for β-catenin as a critical mediator of the metastatic process.
The importance of β-catenin in ErbB2 tumor induction is further supported by studies with the ICG-001 small molecule inhibitor that specifically antagonizes the interaction of ȕ-catenin with CBP but not with p300, facilitating downregulation of a subset of ȕ-catenin/CBP-responsive genes. Treatment with ICG-001 caused a significant proliferative defect in mouse ErbB2 KI mammary tumor cells and in several human ERBB2-overexpressing cancer cells in vitro. Both cell systems showed reduced levels of survivin, which is indicative of antagonized ȕ-catenin/CBP signaling (Fig. 6D, Fig. 7C ). This growth defect was not related to increased apoptosis but rather associated with a defect in cell proliferation. A body of evidence indicates that survivin function is not only limited to inhibition of apoptosis but also involves the regulation of cell division; its overexpression allows cancer cells to resume cell division (reviewed in [48] ). importance of β-catenin in cellular viability, stable cell lines expressing β-catenin-specific shRNAs still retained basal level expression of β-catenin (Fig. 6C, S4C-D) . Given the ability of β-catenin to recruit histone remodelling complexes such as SWI/SNF and Polycomb repressor complexes 1 and 2 (PCR1/2) [49] [50] [51] , it is conceivable that downregulation of β-catenin in ErbB2
KI tumor cells results in genome-wide reprogramming due to an altered epigenetic landscape which compensates for loss of β-catenin. As a consequence these cells maintained their proliferative properties but lost their invasive potential. Further experiments are needed to enhance our understanding of β-catenin signal integration and crosstalk in ErbB2-overexpressing tumor cells.
The complexity by which ȕ-catenin regulates Wnt-dependent and -independent transcription has only emerged recently (reviewed by [52] ). Aberrant activation of the Wnt pathway leads to nuclear localization of ȕ-catenin where it functions as a scaffold to link TCF factors with numerous complexes to regulate target genes. In this study, we have found that loss of endogenous ȕ-catenin in mouse ErbB2 KI tumor cells correlated with low expression of ErbB2, Grb7, Stard3, PerlD1, and ErbB3 (Fig. 6C) . Similarly, inhibition of ȕ-catenin/CBP signaling by ICG-001 in this system significantly suppresses ERBB2, Grb7 and ERBB3 expression in a panel of human ERBB2-overexpressing tumor cells (Fig. 6D, 7C) . Moreover, our ChIP data also illustrate a possible regulation of ERBB2 gene expression by ȕ-catenin/CBP signaling (Fig. 7D) . We found recruitment of ȕ-catenin and RNA polymerase II at an intronic ERBB2 site, which was further enhanced upon Wnt3 exposure while ICG-001 treatment disrupted RNA polymerase II occupancy at this site. This site is particularly important since transcription factors such as ERRα and ERα have been shown to compete for binding to this site to activate or repress ERBB2 transcription [18, 38] . In addition, recent data has established that ERRĮ, ȕ-catenin, and Lef1 form a transcriptionally active complex to activate gene expression [53] . Taken together, the strong reduction of ERBB2 expression observed upon ablation of β-catenin activity either through RNA interference or IGC-001 is due to a disruption of the ERRα/ȕ-catenin/CBP-dependent recruitment of RNA polymerase II to an intronic ERBB2 site that regulates ERBB2 transcription. Consistent with this data, it has been previously demonstrated that ICG-001 specifically interferes with the ability of β-catenin to form complexes with CBP and Lef1 [54] . The ICG-001-dependent reduction in GRB7 transcription can also be attributed to the fact that the proximal promoters of GRB7 and other ERBB2 amplicon components are also regulated by these β-catenin-containing complexes (Suppl. Figure S6 D and E). 
